Cantor Fitzgerald Forecasts Ardelyx FY2025 Earnings

Ardelyx, Inc. (NASDAQ:ARDX) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Ardelyx in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen expects that the biopharmaceutical company will post earnings of ($0.13) per share for the year. The consensus estimate for Ardelyx’s current full-year earnings is ($0.17) per share.

ARDX has been the subject of a number of other research reports. Jefferies Financial Group lowered their price target on Ardelyx from $11.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, January 2nd. Citigroup reduced their price target on Ardelyx from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $5.50 target price on shares of Ardelyx in a research report on Thursday, January 16th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.25.

Ardelyx Stock Performance

Ardelyx stock opened at $4.91 on Wednesday. The company has a market capitalization of $1.16 billion, a PE ratio of -16.37 and a beta of 0.85. The firm has a fifty day simple moving average of $5.15 and a two-hundred day simple moving average of $5.65. The company has a quick ratio of 3.87, a current ratio of 4.03 and a debt-to-equity ratio of 0.64. Ardelyx has a twelve month low of $4.32 and a twelve month high of $10.13.

Insider Transactions at Ardelyx

In other news, insider David P. Rosenbaum sold 27,172 shares of the company’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $5.95, for a total value of $161,673.40. Following the completion of the transaction, the insider now owns 153,616 shares of the company’s stock, valued at $914,015.20. This represents a 15.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael Raab sold 25,000 shares of Ardelyx stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $5.91, for a total transaction of $147,750.00. Following the sale, the chief executive officer now owns 1,210,108 shares in the company, valued at approximately $7,151,738.28. The trade was a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 218,358 shares of company stock valued at $1,189,516 over the last quarter. 5.90% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Ardelyx

Hedge funds have recently bought and sold shares of the business. Inspire Investing LLC increased its position in shares of Ardelyx by 32.8% during the 4th quarter. Inspire Investing LLC now owns 79,423 shares of the biopharmaceutical company’s stock valued at $403,000 after purchasing an additional 19,630 shares during the last quarter. SG Americas Securities LLC raised its position in Ardelyx by 41.8% in the 4th quarter. SG Americas Securities LLC now owns 54,886 shares of the biopharmaceutical company’s stock worth $278,000 after purchasing an additional 16,182 shares during the period. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Ardelyx by 25.5% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 808,392 shares of the biopharmaceutical company’s stock worth $4,099,000 after acquiring an additional 164,480 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Ardelyx by 1.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 387,144 shares of the biopharmaceutical company’s stock valued at $2,667,000 after acquiring an additional 6,093 shares during the period. Finally, B. Riley Wealth Advisors Inc. increased its stake in Ardelyx by 3.4% in the third quarter. B. Riley Wealth Advisors Inc. now owns 90,000 shares of the biopharmaceutical company’s stock worth $599,000 after purchasing an additional 3,000 shares during the period. Hedge funds and other institutional investors own 58.92% of the company’s stock.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company’s lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.